[The prolonged administration of intravenous immunoglobulins as a treatment for refractory fistulous Crohn's diseases].
Fistulating Crohn's disease is present in 17-35% of non-surgically treated patients and in up to 45% of surgically treated ones. Among the several therapeutic alternatives for this disease is intravenous immunoglobulin administration. We present a 28-year-old woman with refractory fistulating Crohn's disease who improved after prolonged immunoglobulin administration (32 months).
González-Lara
V
V
Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid.
Carneros
J A
JA
Núñez-Martínez
O
O
Rodríguez
C
C
Escudero
M
M
Alvarez
R
R
D000328:Adult; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D017577:Cutaneous Fistula / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007077:Ileal Diseases / Q000188:drug therapy* / Q000209:etiology; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction; D013997:Time Factors; D001747:Urinary Bladder Fistula / Q000188:drug therapy* / Q000209:etiology
D016756:Immunoglobulins, Intravenous